News

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...
Hims & Hers Health (NYSE: HIMS), once a niche telehealth provider focused on men’s wellness, has rapidly transformed into a formidable player in the broader digital health ecosystem. HIMS stock has ...
Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...
Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook ...
Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But the company ...
Hims is doubling down on ambitionand it just brought in a heavy hitter to do it. Nader Kabbani, the architect behind Amazon ...
Hims & Hers Health appoints former Amazon executive Nader Kabbani as its chief operating officer. The telehealth-consultation platform on Monday said Kabbani will oversee operations as the company ...
Hims & Hers Health on Monday announced Nader Kabbani, a former Amazon executive who helped establish many of its health-care offerings, will join the telehealth company as its chief operations officer ...
Ezra's primary competitor is Prenuvo, another full-body MRI scanning startup. In February, Prenuvo announced that it closed a ...
which has a long list of candidates in clinical trials trying to chase down the current crop of injectables led by Novo Nordisk’s Wegovy (semaglutide) and Lilly’s Zepbound (tirzepatide).
If approved for the new indication, it could add a major new growth driver for semaglutide, which is already seeing sales rocket on the back of its use as Ozempic for diabetes, Wegovy for obesity ...